CD274 and gastric cancer: The results of the JAVELIN Gastric-100 study indicated that avelumab maintenance did not significantly improve OS compared with the continuation of chemotherapy, and this was observed in advanced GC or GEJC patients, both in the overall study population and in a predefined PD-L1-positive subgroup [45].